Agenus (AGEN) Shares Active as Glaxo (GSK) Submits Shingrix BLA to U.S. FDA

October 24, 2016 7:43 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Agenus (NASDAQ: AGEN) shares are up around 6 percent in early trading Monday as GlaxoSmithKline (NYSE: GSK) announced that it submitted a Biologics License Application (BLA) for its candidate shingles vaccine, Shingrix, to the United States Food and Drug Administration (FDA), seeking approval for the prevention of herpes zoster (shingles) in people aged 50 years or over.

In part, the Glaxo press release read: The GSK proprietary AS01 adjuvant system contains QS-21 Stimulon® adjuvant licensed from Antigenics LLC, a wholly owned subsidiary of Agenus Inc., MPL and liposomes.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Trader Talk

Add Your Comment